Elucidation of marine fungi derived anthraquinones as mycobacterial mycolic acid synthesis inhibitors: an in silico approach
- 33 Downloads
Tuberculosis (TB) is a leading cause of mortality amongst infectious diseases. While the anti-TB drugs can cure TB, the non-compliance and rapidly increasing resistance is of serious concern. The study aimed to search novel potent inhibitor(s) against MabA and PKS18 targets of Mycobacterium tuberculosis (M.tb.) by virtual screening of anthraquinones from marine fungi. The target proteins MabA and PKS18 involved in M.tb. mycolic acid biosynthesis were retrieved from RCSB Protein Data Bank. Chemical structures of 100 marine fungal anthraquinones were retrieved from the PubChem database. These were filtered through Lipinski’s rule of five (for druglikeness) and in silico ADME/Tox analysis (for pharmacokinetic properties) and subjected to molecular docking analysis using AutoDock 4.2. The molecular interaction revealed averufin to possess dual inhibitory potential against M.tb. MabA and PKS18 with binding energy of − 8.84 kcal/mol and − 8.23 kcal/mol, and Ki values of 1.79 and 3.12 µM respectively. Averufin exhibits improved drug-like properties, ADMET profile and binding affinity to both targets as compared to control drugs. Our study suggests that averufin a natural anthraquinone, satisfies all the in silico parameters tested and is expected to efficiently inhibit M.tb. mycolic acid pathway. It might therefore emerge as a promising dual-targeted, novel natural anti-TB lead in future.
KeywordsMarine fungi Anthraquinones Mycobacterium tuberculosis Pharmacokinetics Drug likeness Molecular docking
Authors are thankful to Department of Science and Technology, Govt. of India for infrastructural support to the Department of Biosciences, Integral University under Fund for Improvement of S&T Infrastructure (FIST) program. The Integral University Communication Cell is also gratefully acknowledged for quick and crisp review of manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Global Tuberculosis Report (2017) http://www.who.int/tb/publications /global_report/MainText_13Nov2017.pdf. Accessed 3 Nov 2017
- 10.Felix CR, Gupta R, Geden S, Roberts J, Winder P, Pomponi SA, Diaz MC, Reed JK, Wright AE, Rohde KH (2017) Selective killing of dormant Mycobacterium tuberculosis by marine natural products. Antimicrob Agents Chemother 61(8):e00743–e00717Google Scholar
- 14.Khan N, Karodi R, Siddiqui A, Thube S, Rub R (2011) Development of anti-acne gel formulation of anthraquinones rich fraction fromRubia cordifolia (Rubiaceae). Int J Appl Res Nat Prod 4(4):28–36Google Scholar
- 17.Wang F, Qiao Y, Niu H, Zhao H (2017) Anti-arthritic effect of total anthraquinones from Polygonum cuspidatum on type II collagen-induced arthritis in rats. Trop J Pharm Res 16(10):2453–2459Google Scholar
- 18.Wuthi-udomlert M, Kupittayanant P, Gritsanapan W (2010) In vitro evaluation of antifungal activity of anthraquinone derivatives of Senna alata. J Health Res 24(3):117–122Google Scholar
- 28.Molinspiration C (2016) http://www.molinspiration.com/cgi-bin/properties
- 31.Basso LA, Santos DS (2005) Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis: an update. Med Chem Rev 2:393–413Google Scholar
- 33.Chan RY, Kwok AK (2006) Ocular toxicity of ethambutol. Hong Kong Med J 12(1):56–60Google Scholar
- 34.Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nuñez-Garbin A et al (2011) Factors associated with anti-tuberculosis medication adverse effects: a case–control study in Lima, Peru. PLoS ONE, 6(11), e27610Google Scholar